AR034269A1 - Nuevos 7-azaindoles, su uso como inhibidores de la fosfodiesterasa 4 y el procedimiento para su preparacion, los medicamentos que los contienen y su preparacion - Google Patents

Nuevos 7-azaindoles, su uso como inhibidores de la fosfodiesterasa 4 y el procedimiento para su preparacion, los medicamentos que los contienen y su preparacion

Info

Publication number
AR034269A1
AR034269A1 ARP010105014A ARP010105014A AR034269A1 AR 034269 A1 AR034269 A1 AR 034269A1 AR P010105014 A ARP010105014 A AR P010105014A AR P010105014 A ARP010105014 A AR P010105014A AR 034269 A1 AR034269 A1 AR 034269A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
mono
polysubstituted
unsubstituted
Prior art date
Application number
ARP010105014A
Other languages
English (en)
Original Assignee
Elbion Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10053275A external-priority patent/DE10053275A1/de
Application filed by Elbion Ag filed Critical Elbion Ag
Publication of AR034269A1 publication Critical patent/AR034269A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

Se describen 7-azaindoles de fórmula (1), en la cual: n puede ser 1 ó 2; y R1 es a) alquilo C1-10, de cadena recta o ramificada, insustituido o mono o polisustituido con -OH, -SH, -NH2, -NH-alquilo C1-6, -N(alquilo C1-6)2, -NH-arilo C6-14, -N(arilo C6-14)2, -N(alquil C1-6)(arilo C6-14), -NO2, -CN, -F, -Cl, -Br, -I, -O-alquilo C1-6, -O-arilo C6-14, -S-alquilo C1-6, -S-arilo C6-14, -SO3H, -SO2-alquilo C1-6, -SO2-arilo C6-14, -OSO2alquilo C1-6, -OSO2arilo C6-14, -COOH, -C(O)alquilo C1-5, con carbociclos mono, bi o tricíclicos saturados o mono o poliinsaturados con 3-14 miembros del anillo, con heterociclos mono, bi o tricíclicos saturados o mono o poliinsaturados con 5-15 miembros del anillo y 1-6 heteroátomos que preferentemente son N, O y S, donde los grupos arilo C6-14 y los sustituyentes carbocíclicos y heterocíclicos pueden estar, a su vez, insustituidos o mono o polisustituidos con R4; ó b) alquenilo C2-10, mono o poliinsaturado, de cadena recta o ramificada, insustituido o mono o polisustituido con -OH, -SH, -NH2, -NH-alquilo C1-6, -N(alquilo C1-6)2, -NH-arilo C6-14, -N(arilo C6-14)2, -N(alquil C1-6)(arilo C6-14), -NO2, -CN, -F, -Cl, -Br, -I, -O-alquilo C1-6, -O-arilo C6-14, -S-alquilo C1-6, -S-arilo C6-14, -SO3H, -SO2-alquilo C1-6, -SO2-arilo C6-14, -OSO2alquilo C1-6, -OSO2arilo C6-14, -COOH, -C(O)alquilo C1-5, con carbociclos mono, bi o tricíclicos saturados o mono o poliinsaturados con 3-14 miembros del anillo, con heterociclos mono, bi o tricíclicos saturados o mono o poliinsaturados con 5-15 miembros del anillo y 1-6 heteroátomos que preferentemente son N, O y S, donde los grupos arilo C6-14 y los sustituyentes carbocíclicos y heterocíclicos pueden estar, a su vez, insustituidos o mono o polisustituidos con R4; R2 y R3 pueden ser iguales o diferentes, donde sólo uno de los dos puede ser hidrógeno, y R2 y R3 pueden ser, además, a) alquilo C1-5, insustituido o mono o polisustituido con -OH, -SH, -NH2, -NH-alquilo C1-6, -N(alquilo C1-6)2, -NO2, -CN, -F, -Cl, -Br, -I, -O-alquilo C1-6, -S-alquilo C1-6, -fenilo, y -piridilo; b) fenilo, insustituido o mono o polisustituido con -OH, -SH, -NH2, -NH-alquilo C1-3, -N(alquilo C1-3)2, -NO2, -CN, -COOH, -COOalquilo C1-3, -F, -Cl, -Br, -O-alquilo C1-3, y -S-alquilo C1-3; c) piridilo, insustituido o mono o polisustituido con -NO2, -CN, -COOH, -COOalquilo C1-3, -Cl, -Br, -O-alquilo C1-3, y -S-alquilo C1-3; así como d) un compuesto seleccionado de las fórmulas (2) a (5); además el grupo -NR2R3 puede ser un resto seleccionado de las fórmulas (6) a (9); y R4 es -H, -OH, -SH, -NH2, -NHalquilo C1-6, -N(alquilo C1-6)2, -NHarilo C6-14, -N(arilo C6-14)2, -N(alquil C1-6)(arilo C6-14), -NCOalquilo C1-6, -NO2, -CN, -COOH, -COOalquilo C1-6, -(CO)alquilo C1-6, -(CS)alquilo C1-6, -F, -Cl, -Br, -I, -O-alquilo C1-6, -O-arilo C6-14, -S-alquilo C1-6, -S-arilo C6-14, -SOalquilo C1-6, y -SO2alquilo C1-6. También se describen las sales fisiológicamente tolerables de los compuestos de fórmula (1), el procedimiento para prepararlas, el uso de las mismas para preparar medicamentos, los medicamentos que las contienen y su preparación. Los compuestos de fórmula (1) son útiles como inhibidores de la fosfodiesterasa 4 y, por tanto, son útiles para tratar inflamaciones de las articulaciones, incluyendo artritis y artritis reumatoidea, y para tratar infecciones virales y parasitárias.
ARP010105014A 2000-10-27 2001-10-26 Nuevos 7-azaindoles, su uso como inhibidores de la fosfodiesterasa 4 y el procedimiento para su preparacion, los medicamentos que los contienen y su preparacion AR034269A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10053275A DE10053275A1 (de) 2000-10-27 2000-10-27 Neue 7-Azaindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
US24434200P 2000-10-30 2000-10-30

Publications (1)

Publication Number Publication Date
AR034269A1 true AR034269A1 (es) 2004-02-18

Family

ID=26007507

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010105014A AR034269A1 (es) 2000-10-27 2001-10-26 Nuevos 7-azaindoles, su uso como inhibidores de la fosfodiesterasa 4 y el procedimiento para su preparacion, los medicamentos que los contienen y su preparacion

Country Status (28)

Country Link
US (3) US7169787B2 (es)
EP (1) EP1330455B1 (es)
JP (1) JP4233322B2 (es)
KR (2) KR100837099B1 (es)
CN (1) CN1247576C (es)
AR (1) AR034269A1 (es)
AT (1) ATE301121T1 (es)
AU (2) AU2175302A (es)
BG (1) BG66169B1 (es)
BR (1) BR0114903A (es)
CA (1) CA2428468C (es)
CZ (1) CZ20031146A3 (es)
DE (1) DE50106993D1 (es)
DK (1) DK1330455T3 (es)
EE (1) EE05271B1 (es)
ES (1) ES2246349T3 (es)
HK (1) HK1053839A1 (es)
HR (1) HRP20030427B1 (es)
HU (1) HUP0303034A3 (es)
IL (2) IL155386A0 (es)
MX (1) MXPA03003624A (es)
NO (1) NO324947B1 (es)
NZ (1) NZ525369A (es)
PL (1) PL213999B1 (es)
PT (1) PT1330455E (es)
SK (1) SK287774B6 (es)
TW (1) TWI262920B (es)
WO (1) WO2002034747A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
MXPA05004780A (es) * 2002-11-06 2005-10-05 Celgene Corp Metodos y composiciones que usan farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de canceres y otros padecimientos.
DE10318610A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 7-Azaindole und deren Verwendung als Therapeutika
US20050054691A1 (en) * 2003-08-29 2005-03-10 St. Jude Children's Research Hospital Carboxylesterase inhibitors
BRPI0414313A (pt) * 2003-09-11 2006-11-07 Kemia Inc inibidores de citocinas
JP2008503446A (ja) 2004-05-06 2008-02-07 プレキシコン，インコーポレーテッド Ｐｄｅ４ｂ阻害剤及びその使用
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
CA2583428A1 (en) * 2004-09-03 2006-03-09 Plexxikon, Inc. Bicyclic heteroaryl pde4b inhibitors
BRPI0618643A2 (pt) 2005-11-09 2011-09-06 Combinatorx Inc composição compreendendo um par de fármacos, composição compreendendo um corticosteróide e um imunossupressor dependente de imunofilina não-esteróide, kits e uso
GB0525143D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
JP5682051B2 (ja) 2006-05-18 2015-03-11 ファーマサイクリックス，インク． 細胞内キナーゼ阻害剤
US20100056791A1 (en) * 2006-09-01 2010-03-04 Yasushi Kohno Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same
US8012992B2 (en) * 2008-06-30 2011-09-06 Allergan, Inc. Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
WO2010033981A2 (en) * 2008-09-22 2010-03-25 Isis Innovation Ltd. 5-azaindole bisphosphonates
JP2013503132A (ja) * 2009-08-26 2013-01-31 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング メチルピロロピリジンカルボキサミド
WO2012072727A1 (en) 2010-12-03 2012-06-07 Biotie Therapies Gmbh Crystalline modification of n-(3,5-dichloropyridin-4-yl)-[1-(4 -fluorobenzyl)-7-azaindol-3-yl)]glyoxylic acid amide as inhibitor of pde4
WO2012080329A1 (en) 2010-12-17 2012-06-21 Biotie Therapies Gmbh Formulations of n-(3,5-dichloropyridin-4-yl)-[1-(4-fluorobenzyl)-7-azaindol-3-yl)]glyoxylic acid amide
CN102584842A (zh) * 2011-01-17 2012-07-18 北京大学 取代吲哚并内酰胺衍生物的制备及作为抗疟疾剂的用途
CN113679717A (zh) 2012-08-22 2021-11-23 康奈尔大学 用于抑制肌成束蛋白的方法
US9573946B2 (en) * 2014-02-20 2017-02-21 Novita Pharmaceuticals, Inc. Compounds and methods for inhibiting fascin
CN113164487A (zh) * 2018-10-12 2021-07-23 内布拉斯加大学董事委员会 磷酸二酯酶抑制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1141949A (en) 1966-02-23 1969-02-05 Sterling Drug Inc 7-azaindole derivatives
WO1991009598A1 (en) 1990-01-05 1991-07-11 Pfizer Inc. Azaoxindole derivatives
US5023265A (en) * 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
US5811432A (en) * 1990-11-09 1998-09-22 Pfizer Inc Azaoxindole derivatives
JP3775684B2 (ja) 1992-07-28 2006-05-17 ローン−プーラン・ロレ・リミテツド 脂肪族−またはヘテロ原子−含有連結基によりアリールまたはヘテロアリールに連結されたフェニル含有化合物
HUT71553A (en) * 1992-08-06 1995-12-28 Warner Lambert Co 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
JP3119758B2 (ja) * 1993-02-24 2000-12-25 日清製粉株式会社 ７−アザインドール誘導体及びこれを有効成分とする抗潰瘍薬
WO1995028926A1 (en) 1994-04-21 1995-11-02 Schering Aktiengesellschaft Pde iv inhibitors for treating multiple sclerosis
GB9420521D0 (en) 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
GB9507297D0 (en) 1995-04-07 1995-05-31 Rh Ne Poulenc Rorer Limited New composition of matter
JPH09169665A (ja) 1995-12-21 1997-06-30 Kenichi Miyamoto 骨粗鬆症治療剤
JP3601898B2 (ja) 1996-02-14 2004-12-15 俊隆 鍋島 薬物依存形成抑制剤
AUPO282996A0 (en) 1996-10-07 1996-10-31 Fujisawa Pharmaceutical Co., Ltd. Novel compounds
AU3868500A (en) * 1999-03-10 2000-09-28 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone

Also Published As

Publication number Publication date
IL155386A0 (en) 2003-11-23
BR0114903A (pt) 2003-10-14
KR100880586B1 (ko) 2009-01-30
JP4233322B2 (ja) 2009-03-04
JP2004512337A (ja) 2004-04-22
NO20031722D0 (no) 2003-04-14
PL213999B1 (pl) 2013-06-28
EE200300166A (et) 2003-08-15
BG107725A (bg) 2004-08-31
SK5092003A3 (en) 2004-08-03
HRP20030427B1 (en) 2006-04-30
EE05271B1 (et) 2010-02-15
CN1247576C (zh) 2006-03-29
NO324947B1 (no) 2008-01-07
DK1330455T3 (da) 2005-12-05
CN1484644A (zh) 2004-03-24
HRP20030427A2 (en) 2003-08-31
US7683074B2 (en) 2010-03-23
IL155386A (en) 2008-06-05
NO20031722L (no) 2003-04-14
US20080207680A1 (en) 2008-08-28
AU2002221753B2 (en) 2006-12-14
PL362837A1 (en) 2004-11-02
CZ20031146A3 (cs) 2003-10-15
KR20080016758A (ko) 2008-02-21
PT1330455E (pt) 2005-10-31
EP1330455B1 (de) 2005-08-03
HUP0303034A2 (hu) 2003-12-29
US7419987B2 (en) 2008-09-02
ES2246349T3 (es) 2006-02-16
WO2002034747A1 (de) 2002-05-02
HK1053839A1 (en) 2003-11-07
MXPA03003624A (es) 2004-12-02
HUP0303034A3 (en) 2012-12-28
EP1330455A1 (de) 2003-07-30
KR20030065499A (ko) 2003-08-06
AU2175302A (en) 2002-05-06
KR100837099B1 (ko) 2008-06-13
NZ525369A (en) 2004-09-24
TWI262920B (en) 2006-10-01
BG66169B1 (bg) 2011-10-31
SK287774B6 (sk) 2011-09-05
ATE301121T1 (de) 2005-08-15
US20060258700A1 (en) 2006-11-16
US20040106641A1 (en) 2004-06-03
CA2428468C (en) 2011-06-14
CA2428468A1 (en) 2002-05-02
US7169787B2 (en) 2007-01-30
DE50106993D1 (de) 2005-09-08

Similar Documents

Publication Publication Date Title
AR034269A1 (es) Nuevos 7-azaindoles, su uso como inhibidores de la fosfodiesterasa 4 y el procedimiento para su preparacion, los medicamentos que los contienen y su preparacion
ES2185185T3 (es) Nuevos compuestos espiroazabiciclicos heterociclicos.
BR0114223A (pt) Derivados de sulfonamida, farmaceuticamente ativos, possuindo grupos lipofìlicos e ionizáveis como inibidores de junkinases de proteìnas, uso de um derivado de sulfonamida, composição farmacêutica, contendo pelo menos um derivado de sulfonamida, processo para a preparação de um derivado de sulfonamida e compostos de sulfonamida
PT83310B (pt) Processo para a preparacao de derivados de indol heterociclicamente substituiods, de produtos intermediarios para a sua preparacao e de composicoes farmaceuticas que os contem
AR004219A1 (es) Nuevos derivados de quinazolina, procedimientos para su preparacion, composiciones que los contienen y su uso en la preparacion de medicamentos,particularmente en el tratamiento de trastornos inflamatorios
PT93552A (pt) Processo para a preparacao de derivados de pirrol acriloil-substituidos e de composicoes farmaceuticas que os contem
PE99698A1 (es) Derivados del acido arilsulfonilamino hidroxamico
PE20020476A1 (es) Derivados de glucopiranosiloxibencilbenceno y composiciones farmaceuticas que comprenden los mismos
AR036114A1 (es) Tetrahidroimidazol[1,2-a]pirazinas y tetrahidrotriazol[4,3-a]pirazinas como inhibidores de la dipeptidil peptidasa utiles para el tratamiento o la prevencion de la diabetes
AR245447A1 (es) Procedimiento para preparar derivados de 2,4-diamino-5-(biciclo-sustituido)metilpirimidinas.
AR035790A1 (es) Compuesto derivado de pirazolo[3,4-d]pirimidina y metodo para preparar un compuesto intermediario
ATE29255T1 (de) Succinimid-derivate und deren herstellung.
PE20001562A1 (es) Derivados de benzamida como inhibidores de la produccion hepatica de la apo proteina b-100
PE20040698A1 (es) Derivados de isoindolina
AR036176A1 (es) Un derivado de fenil-acetamido-tiazol, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un producto o kit que los comprende, y un metodo que utiliza dicho derivado
AR047094A1 (es) Derivados de diarilmetil piperazina, sus preparaciones y sus usos
ES523418A0 (es) Un metodo para preparar compuestos de piridilo
AR018632A1 (es) Compuestos derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene, proceso para su preparacion.
ES2032335T3 (es) Nuevos derivados flavonoides 2-piperazinil-2-oxo-etilen sustituidos, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen.
AR044080A1 (es) 7-azaindoles y su uso como medicamentos
AR019256A1 (es) Utilizacion de derivados tetraciclo[6-6-2-0(2.27).0(9.14)] hexadeca-2(7), 3, 5, 9(14), 10,12-hexaeno, para la preparacion de preparados farmaceuticos conaccion inhibitoria de la fosfolipasa, los referidos derivados y preparado farmaceutico que contiene por lo menos a uno de dichos derivados
ES2179475T3 (es) Nuevos derivados de la eritromicina, su procedimiento de preparacion ysu aplicacion como medicamentos.
AR044079A1 (es) 5- hidrxiindoles con grupos de n- oxido, su empleo como terapeuticos y procedimientos para su preparacion
ES8606363A1 (es) Un procedimiento de preparar derivados de acido 1-destia-2- tiacefalosporanico
MX9405111A (es) Nuevos derivados de (1-fenil-1-heterociclil)metanol y(1-fenil-1-heterociclil-metilamina).

Legal Events

Date Code Title Description
FG Grant, registration